Occult HBV infection in anti-HBs-positive young adults after neonatal HB vaccination

Vaccine

Volumn 28, Issue 37, 2010, Pages 5986-5992

  Xu, Libin ^a,c   Wei, Yong ^a   Chen, Taoyang ^b   Lu, Jianhua ^b   Zhu, Chang Lin ^a   Ni, Zhengping ^b   Huang, Fei ^b   Du, Jun ^a   Sun, Zongtang ^a   Qu, Chunfeng ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b QIDONG LIVER CANCER INSTITUTE   (China)

^c CANCER HOSPITAL   (China)

Author keywords

Anti HBs positive; Neonatal HB vaccination; Occult HBV infection

Indexed keywords

EPITOPE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; VIRUS DNA; HEPATITIS VACCINE;

ADULT; ARTICLE; FEMALE; GENE MUTATION; HEPATITIS B; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS LOAD; AMINO ACID SEQUENCE; BLOOD; CHINA; GENETICS; GENOTYPE; MOLECULAR GENETICS; MUTATION; YOUNG ADULT;

AMINO ACID SEQUENCE; CHINA; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; VIRAL HEPATITIS VACCINES; YOUNG ADULT;

EID: 77955508817     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.106     Document Type: Article

References (38)

1. CDC Progress in hepatitis B prevention through universal infant vaccination - China, 1997-2006. MMWR Wkly 2007, 56(May (18)):441-445.
2. Zhou Y.H., Wu C., Zhuang H. Vaccination against hepatitis B: the Chinese experience. Chin Med J (Engl) 2009, 122(January (1)):98-102.
3. Lu F.M., Zhuang H. Management of hepatitis B in China. Chin Med J (Engl) 2009, 122(January (1)):3-4.
4. Sun Z., Ming L., Zhu X., Lu J. Prevention and control of hepatitis B in China. J Med Virol 2002, 67(July (3)):447-450.
5. Banatvala J.E., Van Damme P. Hepatitis B vaccine - do we need boosters?. J Viral Hepat 2003, 10(January (1)):1-6.
6. Yuen M.F., Lim W.L., Chan A.O., Wong D.K., Sum S.S., Lai C.L. 18-Year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2004, 2(October (10)):941-945.
7. Zanetti A.R., Mariano A., Romano L., D'Amelio R., Chironna M., Coppola R.C., et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005, 366(October (9494)):1379-1384.
8. Lu C.Y., Ni Y.H., Chiang B.L., Chen P.J., Chang M.H., Chang L.Y., et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008, 197(May (10)):1419-1426.
9. Jan C.F., Huang K.C., Chien Y.C., Greydanus D.E., Davies H.D., Chiu T.Y., et al. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology 2010, 51(May (5)):1547-1554.
10. Raimondo G., Pollicino T., Romano L., Zanetti A.R. A 2010 update on occult hepatitis B infection. Pathol Biol (Paris) 2010, March.
11. Brechot C., Degos F., Lugassy C., Thiers V., Zafrani S., Franco D., et al. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 1985, 312(January (5)):270-276.
12. Nalpas B., Berthelot P., Thiers V., Duhamel G., Courouce A.M., Tiollais P., et al. Hepatitis B virus multiplication in the absence of usual serological markers. A study of 146 chronic alcoholics. J Hepatol 1985, 1(2):89-97.
13. Sanchez-Quijano A., Jauregui J.I., Leal M., Pineda J.A., Castilla A., Abad M.A., et al. Hepatitis B virus occult infection in subjects with persistent isolated anti-HBc reactivity. J Hepatol 1993, 17(March (3)):288-293.
14. Hou J., Wang Z., Cheng J., Lin Y., Lau G.K., Sun J., et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology 2001, 34(November (5)):1027-1034.
15. Hsia C.C., Scudamore C.H., Di Bisceglie A.M., Tabor E. Molecular and serological aspects of HBsAg-negative hepatitis B virus infections in North America. J Med Virol 2003, 70(May (1)):20-26.
16. Gao J.D., Shao Y.F., Xu Y., Ming L., Wu Z., Liu G., et al. Close relation of hepatocellular carcinoma to HBV infection in North China. Chin J Hepatobiliary Surg 2004, 10(6):363-365.
17. Chen J.G., Zhu J., Parkin D.M., Zhang Y.H., Lu J.H., Zhu Y.R., et al. Trends in the incidence of cancer in Qidong, China, 1978-2002. Int J Cancer 2006, 119(September (6)):1447-1454.
18. Sun Z., Zhu Y., Stjernsward J., Hilleman M., Collins R., Zhen Y., et al. Design and compliance of HBV vaccination trial on newborns to prevent hepatocellular carcinoma and 5-year results of its pilot study. Cancer Detect Prev 1991, 15:313-318.
19. Sun Z, Lu J, Lu P, Ming L. Immunological approaches to prevent chronic hepatitis and hepatocellular carcinoma. In: Lam S, Tang Z, editors. Liver diseases in the new millennium I. Gastrolenterol Hepatol 2000; 15(suppl):I:68.
20. Sun T.T., Chu Y.R., Ni Z.Q., Lu J.H., Huang F., Ni Z.P., et al. A pilot study on universal immunization of newborn infants in an area of hepatitis B virus and primary hepatocellular carcinoma prevalence with a low dose of hepatitis B vaccine. J Cell Physiol Suppl 1986, 4:83-90.
21. Kremsdorf D., Garreau F., Duclos H., Thiers V., Schellekens H., Petit M.A., et al. Complete nucleotide sequence and viral envelope protein expression of a hepatitis B virus DNA derived from a hepatitis B surface antigen-seronegative patient. J Hepatol 1993, 18(June (2)):244-250.
22. Kwok S., Higuchi R. Avoiding false positives with PCR. Nature 1989, 339(May (6221)):237-238.
23. Chen J., Yin J., Tan X., Zhang H., Zhang H., Chen B., et al. Improved multiplex-PCR to identify hepatitis B virus genotypes A-F and subgenotypes B1, B2, C1 and C2. J Clin Virol 2007, 38(March (3)):238-243.
24. Norder H., Courouce A.M., Coursaget P., Echevarria J.M., Lee S.D., Mushahwar I.K., et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004, 47(November-December (6)):289-309.
25. Pas S.D., Fries E., De Man R.A., Osterhaus A.D., Niesters H.G. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 2000, 38(August (8)):2897-2901.
26. Carman W.F., Zanetti A.R., Karayiannis P., Waters J., Manzillo G., Tanzi E., et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990, 336(August (8711)):325-329.
27. Fortuin M., Karthigesu V., Allison L., Howard C., Hoare S., Mendy M., et al. Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis 1994, 169(June (6)):1374-1376.
28. Waters J.A., Brown S.E., Steward M.W., Howard C.R., Thomas H.C. Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of a protective antibody response. Virus Res 1992, 22(January (1)):1-12.
29. Howard C.R., Allison L.M. Hepatitis B surface antigen variation and protective immunity. Intervirology 1995, 38(1-2):35-40.
30. Zheng X., Weinberger K.M., Gehrke R., Isogawa M., Hilken G., Kemper T., et al. Mutant hepatitis B virus surface antigens (HBsAg) are immunogenic but may have a changed specificity. Virology 2004, 329(November (2)):454-464.
31. Lu C.Y., Chiang B.L., Chi W.K., Chang M.H., Ni Y.H., Hsu H.M., et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004, 40(December (6)):1415-1420.
32. But D.Y., Lai C.L., Lim W.L., Fung J., Wong D.K., Yuen M.F. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008, 26(December (51)):6587-6591.
33. Weinberger K.M., Bauer T., Bohm S., Jilg W. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J Gen Virol 2000, 81(May (Pt 5)):1165-1174.
34. Osiowy C. Detection of HBsAg mutants. J Med Virol 2006, 78(Suppl 1):S48-51.
35. Hollinger E., Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 2008, 48:1001-1026.
36. Su F.H., Chen J.D., Cheng S.H., Sung K.Y., Jeng J.J., Chu F.Y. Waning-off effect of serum hepatitis B surface antibody amongst Taiwanese university students: 18 years post-implementation of Taiwan's national hepatitis B vaccination programme. J Viral Hepat 2008, 15(January (1)):14-19.
37. Chisari F.V., Ferrari C., Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995, 13:29-60.
38. Mu S.C., Lin Y.M., Jow G.M., Chen B.F. Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. J Hepatol 2009, 50(February (2)):264-272.